142 related articles for article (PubMed ID: 36712659)
21. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Toxicity of Every 2 Weeks Docetaxel Regimen in Comparison With Weekly or Every 3 Weeks in Metastatic Prostate Cancer: A Retrospective Analysis.
Malhotra A; Welch D; Rosenbaum P; Poiesz BJ
Am J Clin Oncol; 2016 Jun; 39(3):266-70. PubMed ID: 24662265
[TBL] [Abstract][Full Text] [Related]
24. Model-informed dose selection for an investigational human epidermal growth factor receptor 2 antibody-drug conjugate FS-1502 in patients with human epidermal growth factor receptor 2-expressing advanced malignant solid tumours.
Sun Y; Li C; Wang X; Zheng Y; Wu Z; Hui AM; Diao L
Br J Clin Pharmacol; 2024 Apr; 90(4):1115-1129. PubMed ID: 37926561
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive-stage small-cell lung cancer.
Chen P; Zhang Y; Wang Y; Ma K; Shi W; Djebli N; Shen K
CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38711252
[TBL] [Abstract][Full Text] [Related]
26. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
27. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study.
Huang J; Shi G; Wang Y; Wang P; Zhang J; Kong W; Huang Y; Wang S; Xue W
Future Oncol; 2022 Apr; 18(12):1461-1471. PubMed ID: 35103528
[TBL] [Abstract][Full Text] [Related]
28. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.
Chen J; Hu X; Li Q; Dai W; Cheng X; Huang W; Yu W; Chen M; Guo Y; Yuan G
Ann Transl Med; 2020 Sep; 8(18):1187. PubMed ID: 33241036
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch.
Xu H; Tong X; Mugundu G; Scott ML; Cook C; Arfvidsson C; Pease E; Zhou D; Lyne P; Al-Huniti N
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):65-74. PubMed ID: 30661177
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
[TBL] [Abstract][Full Text] [Related]
33. Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting.
Kato R; Ikarashi D; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Tokuyama R; Tamai K; Harigai N; Nakazaki Y; Obara W
Transl Oncol; 2020 Jun; 13(6):100771. PubMed ID: 32375081
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
[TBL] [Abstract][Full Text] [Related]
35. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
[TBL] [Abstract][Full Text] [Related]
36. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ; Kumarakulasinghe NB; Muthu V; Lee M; Walsh R; Low JL; Choo J; Tan HL; Chong WQ; Ang Y; Chan G; Yong WP; Huang Y; Ngoi N; Wong A
Oncology; 2021; 99(3):192-202. PubMed ID: 33440374
[TBL] [Abstract][Full Text] [Related]
37. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.
Sheng J; Zhang J; Baudelet C; Roy A
J Clin Pharmacol; 2021 Aug; 61(8):1045-1053. PubMed ID: 33501654
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
Proctor JR; Gartner EM; Gray TE; Davies RH
Cancer Chemother Pharmacol; 2022 Nov; 90(5):399-408. PubMed ID: 36102999
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
40. Toripalimab in advanced biliary tract cancer.
Li W; Wang Y; Yu Y; Li Q; Wang Y; Zhang C; Xu X; Guo X; Dong Y; Cui Y; Hao Q; Huang L; Liu H; Liu T
Innovation (Camb); 2022 Jul; 3(4):100255. PubMed ID: 35615603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
